IPO
Key Metrics
Market cap
~$1.39B (Sept 2026)
As of Sep 2026EstimatedValue Add Pulse research
Total funding
$135M Series A + $150M Series B + $345.6M IPO
As of Sep 9, 2026Value Add Pulse research
Company Snapshot
Latigo Biotherapeutics is a Biotech company, based in Thousand Oaks, California, USA, founded 2018. Market cap ~$1.39B (Sept 2026) (As of Sep 2026, Value Add Pulse research). Total funding $135M Series A + $150M Series B + $345.6M IPO (As of Sep 9, 2026).
Recent changes
- Sep 2026Sep 2026First reported market cap: ~$1.39B (Sept 2026)Estimated Value Add Pulse enrichment
- Aug 7, 2026Aug 7, 2026IPO $345.6M Bloomberg
- Aug 7, 2026Aug 7, 2026Latigo Biotherapeutics Jumps 17% in $345.6M IPO Pulse story
- Aug 2026Aug 2026First reported total funding: $321.5M (pre-IPO) BioXconomy
- Jan 2025Jan 2025Raised $150M Series B Value Add Pulse enrichment
Earlier changes (2)
- Feb 14, 2024Feb 14, 2024Raised $135M Series A PR Newswire
- Feb 14, 2024Feb 14, 2024New investor: Westlake Village BioPartners PR Newswire
Funding History
3 events · sources dated per row| Date | Event | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| Aug 7, 2026 | IPO | $345.6M | — | Pulse story | |
| Jan 1, 2025 | Series B | $150M | — | Value Add Pulse research | |
| Feb 14, 2024 | Series A | $135M | — | outlined = lead | PR Newswire |
Investors
Latest Pulse
- Aug 10, 2026Biotech IPO Window Closes Its Strongest Week Since SpringBlossomHill and Latigo Biotherapeutics both closed upsized IPOs by August 10, capping a four-deal stretch that also included Braveheart Bio and Attovia Therapeutics pricing above or near the top of their ranges.→
- Aug 7, 2026Latigo Biotherapeutics Jumps 17% in $345.6M IPOLatigo Biotherapeutics priced its upsized IPO at $18 a share for $345.6 million and jumped 17% in its Nasdaq debut, the third biotech offering in two weeks to price above range.→
- Aug 4, 2026Attovia Prices IPO as Biotech's Public Pipeline Fills OutAttovia Therapeutics priced its Nasdaq IPO at $17 a share while Latigo Biotherapeutics advances its own S-1, the latest signs that the biotech listing window is filling with genuine clinical-stage pipelines.→
- Aug 4, 2026Latigo Sets Terms for a $272M Nasdaq IPOLatigo Biotherapeutics set terms for a $272M Nasdaq IPO under ticker LTGO, pricing 16M shares at $16-18 to fund late-stage trials of its non-opioid Nav1.8 pain drug, a rival to Vertex's Journax.→
- Aug 3, 2026Blue Owl-Backed Latigo Advances Nasdaq IPO PlansLatigo Biotherapeutics filed an amended S-1 this week, advancing its Nasdaq IPO to fund a pivotal Phase 3 trial for its non-opioid pain drug ahead of the trial itself starting.→
Coverage Timeline
newest first- Aug 10, 2026IPOBiotech IPO Window Closes Its Strongest Week Since Spring~$972M, 4 deals→
- Aug 7, 2026IPOLatigo Biotherapeutics Jumps 17% in $345.6M IPO$345.6M IPO→
- Aug 4, 2026IPOAttovia Prices IPO as Biotech's Public Pipeline Fills Out$17/share IPO→
- Aug 4, 2026IPOLatigo Sets Terms for a $272M Nasdaq IPO$272M IPO→
- Aug 3, 2026IPOBlue Owl-Backed Latigo Advances Nasdaq IPO Plans→
All Coverage
IPO~$972M, 4 deals
Biotech IPO Window Closes Its Strongest Week Since Spring
BlossomHill and Latigo Biotherapeutics both closed upsized IPOs by August 10, capping a four-deal stretch that also included Braveheart Bio and Attovia Therapeutics pricing above or near the top of their ranges.
FOLLOW-UP
IPO
Latigo Biotherapeutics Jumps 17% in $345.6M IPO
IPO$345.6M IPO
Latigo Biotherapeutics Jumps 17% in $345.6M IPO
Latigo Biotherapeutics priced its upsized IPO at $18 a share for $345.6 million and jumped 17% in its Nasdaq debut, the third biotech offering in two weeks to price above range.
FOLLOW-UP
IPO
Attovia Prices IPO as Biotech's Public Pipeline Fills Out
IPO$17/share IPO
Attovia Prices IPO as Biotech's Public Pipeline Fills Out
Attovia Therapeutics priced its Nasdaq IPO at $17 a share while Latigo Biotherapeutics advances its own S-1, the latest signs that the biotech listing window is filling with genuine clinical-stage pipelines.
IPO
Latigo Sets Terms for a $272M Nasdaq IPO
IPO$272M IPO
Latigo Sets Terms for a $272M Nasdaq IPO
Latigo Biotherapeutics set terms for a $272M Nasdaq IPO under ticker LTGO, pricing 16M shares at $16-18 to fund late-stage trials of its non-opioid Nav1.8 pain drug, a rival to Vertex's Journax.
IPO
Blue Owl-Backed Latigo Advances Nasdaq IPO Plans
IPO
Blue Owl-Backed Latigo Advances Nasdaq IPO Plans
Latigo Biotherapeutics filed an amended S-1 this week, advancing its Nasdaq IPO to fund a pivotal Phase 3 trial for its non-opioid pain drug ahead of the trial itself starting.
Related Companies
Sources & methodologyshow
Where these figures come from
- PR Newswireprimary source1 fact
- Bloombergmajor outlet1 fact
- Value Add Pulse researchValue Add VC data3 facts
Figures are labelled Reported (a source states it), Estimated, Derived (computed from other facts) or Rumored (in talks / unconfirmed). Rumors never replace a confirmed figure. Each figure keeps its own as-of date; history is preserved rather than overwritten.